Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported
➤ Phase 2 trial results of gene therapy for diabetic retinopathy
➤ Phase 2 program for tracking glaucoma biomarkers begins
➤ Results from extension study of the first approved treatment for geographic atrophy
➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy
➤ ASCRS news and events
➤ FDA expands eye drop warning list
➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant
➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis
➤ FDA approves additional treatment indication for bispecific antibody
➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy
➤ Company to study personalized medicine for patients with wet AMD
➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy
➤ Pivotal trial for wet AMD therapy begins
➤ Survey evaluates female ophthalmologist experiences
➤ ASCRS news and events
➤ Editorial statement on the nomenclature for refractive lenticule extraction procedure
➤ First patient dosed in Phase 1/2 trial evaluating allogenic cell therapy for corneal edema
➤ IND granted to company investigating therapy for geographic atrophy
➤ Licensing agreement to develop neuroprotective drug
➤ Retinal imaging test detects increased risk for type of dementia
➤ ASCRS news and events
➤ Study: large-scale MIGS study
➤ Partnership to advance early disease detection
➤ License agreement to move forward option for cataract surgery sedation
➤ Name change news
➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal
➤ Inventors of OCT honored with ‘American Nobel Prize’
➤ Preservative-free latanoprost begins U.S. launch
➤ Enrollment complete in myopia treatment trial
➤ ASCRS news and events
Three ophthalmologists shared their knowledge of malignant glaucoma, why it occurs, its management, and if possible, its prevention. They also discussed some of the misunderstanding that has surrounded this topic.
Manjool Shah, MD, Glaucoma Editor, discussed what topics are covered in the Glaucoma section of the issue and shared a personal story of working with colleagues from NYU’s School of Engineering on ways to evaluate, modify, and potentially design safer surgical devices.
Two experts, including Glaucoma Editor Manjool Shah, MD, spoke about the complications during and after MIGS procedures that the surgeon needs to be prepared to identify and address.
➤ FDA issues eight warning letters
➤ Positive Phase 2 safety update for investigational treatment of retinal diseases
➤ First-in-human titratable glaucoma therapy system
➤ Companies partner to develop biological dry eye treatment
➤ Geographic atrophy drug development discontinued
➤ ASCRS news and events
Neovascular glaucoma (NVG) is an aggressive, secondary glaucoma that develops in the setting of retinal ischemia. Specialists and residents weighed in on what to look for and strategies to manage this condition.
